![](https://www.e-med.co.il/wp-content/uploads/2022/06/default-312x200.jpg)
Adding Trastuzumab to Docetaxel/Cisplatin Reduces Lymph Node Involvement in Advanced Breast Cancer
ORLANDO, FL — May 23, 2002 — Adding the HER2 antagonist trastuzumab to a neoadjuvant treatment regimen
ORLANDO, FL — May 23, 2002 — Adding the HER2 antagonist trastuzumab to a neoadjuvant treatment regimen
ORLANDO, FL — May 23, 2002 — Schering-Plough Research Institute (SPRI) reported results from several early phase
ORLANDO, FL — May 20, 2002 — Interim analyses suggest that imatinib is an effective treatment for
ORLANDO, FL — May 20, 2002 — To achieve maximum benefit, adjuvant tamoxifen therapy should be initiated
ORLANDO, FL — May 20, 2002 — Adding target therapy with the investigational anticancer antibody C225 (Erbitux)
ORLANDO, FL — May 20, 2002 — Patients who received a docetaxel-based treatment for adjuvant therapy of
05/20/2002 By Elda Hauschildt Patients with early invasive cervical adenocarcinoma to a depth of three millimetres or
05/20/2002 By David Ball Transplantation and/or ablation might offer alternative treatments in patients least likely to benefit
Laurie Barclay, MD NEW YORK (MedscapeWire) May 20 The new radioimmunotherapy drug ibritumomab (Zevalin) looks promising
International Journal of Radiation Oncology, Biology and Physics (IJROBP Online) 05/16/2002 By Elda Hauschildt Radiation doses that
נא ציין כתובת דואר אלקטרוני שבה אתה מקבל דיוורי e-Med או זו שציינת בכרטיס האישי שלך.
קישור לאיפוס סיסמא נשלח למייל.
חזרה להתחברות